Anti-ox40 antibodies and methods of use
AssigneeGenentech, Inc.
InventorsChangchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, Kevin WALSH, Patricia DE ALMEIDA, James ANDYA, Ye SHEN
Life of this patent
Estimating the term…
Abstract
The invention provides anti-OX40 antibodies and methods of using the same.
Claims47
1-70. (canceled)
A method of treating an individual having cancer comprising administering to the individual an effective amount of an anti-human OX40 agonist antibody, wherein the antibody comprises:
- (1) a heavy chain variable domain (VH) comprising (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:2;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:3;
- and (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:4;
- and
- (2) a light chain variable domain (VL) comprising (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:5;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:6;
- and (f) an HVR-L3 comprising an amino acid sequence of SEQ ID NO:7.
A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of an anti-angiogenesis agent and an OX40 binding agonist;
- wherein the OX40 binding agonist is an anti-human OX40 agonist antibody comprising:
- (1) a heavy chain variable domain (VH) comprising (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:2;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:3;
- and (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:4;
- and
- (2) a light chain variable domain (VL) comprising (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:5;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:6;
- and (f) an HVR-L3 comprising an amino acid sequence of SEQ ID NO:7.
(canceled)
(canceled)
82-90. (canceled)
93-107. (canceled)
114-146. (canceled)
150-156. (canceled)
166-173. (canceled)
Dependencies are inferred from the claim text.